tirzepatide sglt2 Causes and consequences of discontinuation of GLP1RAs or SGLT2 Inhibitors and GLP-1 Receptor

Ultimately, if the drugs are ever discontinued, and solid diet and exercise habits are not in place, patients may regain the weight they lost and put on even more much like many do after a significant diet

Subandrate, Safyudin, Arifin M, et al

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Because this payment demonstration operates outside coverage under a Part D plan, the $50 copayment toward these medications will not count toward a participating beneficiarys Part D deductible or the $2,100 out-of-pocket maximum in 2026 (increasing to $2,400 in 2027), and copayments will stay consistent at $50 per month, regardless of the Part D benefit phase a beneficiary is in when they fill the prescription

doi: 10.1002/art.1780330203